

## Galapagos increases share capital through subscription right exercises

**Mechelen, Belgium; 4 December 2020, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.**

Galapagos issued 70,925 new ordinary shares on 4 December 2020, for a total capital increase (including issuance premium) of €2,615,857.50.

Pursuant to the subscription right exercise program of Galapagos' management board, members of the management board automatically are committed to exercise a minimum number of subscription rights, subject to certain conditions. In accordance with the rules of this program, CEO Onno van de Stolpe exercised 15,000 subscription rights. Three other management board members exercised an aggregate number of 15,000 subscription rights.

In accordance with Belgian transparency legislation<sup>1</sup>, Galapagos notes that its total share capital currently amounts to €353,819,443.97, the total number of securities conferring voting rights amounts to 65,411,767, which is also the total number of voting rights (the "denominator"), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (formerly known as warrants) to subscribe to not yet issued securities conferring voting rights is (i) 6,928,337 subscription rights under several outstanding employee subscription right plans, which equals 6,928,337 voting rights that may result from the exercise of those subscription rights, and (ii) one subscription right issued to Gilead Therapeutics to subscribe for a maximum number of shares that is sufficient to bring the shareholding of Gilead and its affiliates to 29.9% of the actually issued and outstanding shares after the exercise of the subscription right. Galapagos does not have any convertible bonds or shares without voting rights outstanding.

### About Galapagos

Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at [www.glpq.com](http://www.glpq.com).

### Contacts

#### Investors:

Elizabeth Goodwin  
VP Investor Relations  
+1 781 460 1784

Sofie Van Gijssel  
Senior Director Investor Relations  
+32 485 19 14 15  
[ir@glpg.com](mailto:ir@glpg.com)

#### Media:

Carmen Vroonen  
Global Head of Communications & Public Affairs  
+32 473 824 874

---

<sup>1</sup> Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market

Anna Gibbins  
Senior Director Therapy Areas Communications  
+44 7717 801900  
[communications@glpg.com](mailto:communications@glpg.com)

**Forward-looking statements**

*This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.*